Discovery on Target 2026 has ended. This guide stays up as the record of who was there. Next: Discovery on Target 2027, Oct 18–21, 2027 in Boston

Antibodies against challenging targets at Discovery on Target 2026

Sep 28 – Oct 1, 2026 Boston, MA ~1.1k attendees Website

34 organizations at Discovery on Target 2026 present work in antibodies against challenging targets, led by drug developers. Between them they bring 56 presentations to the program. Most represented: Genentech, University of California, San Francisco and Massachusetts Institute of Technology. As of Oct 8, 2026.

All 510 organizations at Discovery on Target 2026 →

Showing 1–11 of 34 organizations

Organization	Discovery on Target 2026 Attendance
Genentech South San Francisco, CA
gene.com Large pharma Biotechnology company and member of the Roche Group, discovering and developing medicines in oncology, immunology and neuroscience.	Talk Mon Sep 28 10:15am–10:45am AI-empowered Early Target Discovery with MARS: Multimodal Platform for Target Prioritization and Modality Selection Symposium: Generative AI/Machine Learning-Driven Drug Design Talk Tue Sep 29 11:05am–11:35am Molecular Basis of CXC Chemokine Receptor 3 Ligand Multispecificity Antibodies Against Challenging Targets Talk Wed Sep 30 12:20pm–12:50pm Template-Driven Scaffolding of SCFFBXO42 Regulates PP2A Degradation Emerging Drug Targets Talk Wed Sep 30 2:05pm–2:35pm Accelerating T Cell Engager Immunotherapy Discovery with High-Throughput Kinetic Multiparametric Platform Antibodies Against Challenging Targets Talk Thu Oct 1 11:50am–12:20pm Discovery of Novel Activators for Lysosome Ion Channel TMEM175, a Parkinson's-Disease Target Emerging Drug Targets Talk Thu Oct 1 4:05pm–4:35pm Using Metal Ions to Identify Novel PPI Binding Sites Lead Generation Strategies Talk Thu Oct 1 4:35pm–5:05pm Mechanistic Insights into Hit-Selection Based on DEL Screening Lead Generation Strategies
University of California, San Francisco San Francisco, CA
	Panel Mon Sep 28 5:00pm–6:00pm Where and How Can Open Source AI/ML Learning Impact Drug Development? Symposium: Generative AI/Machine Learning-Driven Drug Design · with PsiThera, Ginkgo Bioworks, Eli Lilly +3 more Talk Tue Sep 29 10:35am–11:35am Ninhydrin as a Covalent Warhead-Targeting Arginine Lead Generation Strategies Talk Tue Sep 29 11:35am–12:05pm Snapshots of the Cell Surface: Mapping Protein Neighborhoods Using Contact-dependent Antibody Mapping (contactMAP) Antibodies Against Challenging Targets Talk Wed Sep 30 11:50am–12:20pm Targeted Degradation of Extracellular Proteins via Induced Shedding Novel Drug Modalities Talk Wed Sep 30 12:20pm–12:50pm Making "n=1" Therapies Accessible for All with Computational Target Prediction Innovative Discovery Technologies Talk Thu Oct 1 10:05am–10:35am Structure-Guided Engineering of a Conformation-Specific Antibody–Drug Conjugate for AML Antibodies Against Challenging Targets Talk Thu Oct 1 10:35am–11:05am Chemical Strategies to Expand the Therapeutic Window for Targeted Radiotherapy Radioligand Therapies
Massachusetts Institute of Technology Cambridge, Massachusetts
	Talk Wed Sep 30 9:35am–10:05am Antibody Discovery against Intrinsically Disordered Proteins Antibodies Against Challenging Targets Talk Wed Sep 30 11:50am–12:20pm Peptide–Small Molecule Conjugate Libraries for Hit Discovery and Catalyst Development Next-Generation Conjugates Panel Thu Oct 1 2:25pm–3:20pm Starting Up: Translating Lab Ideas into Commercial Impact Plenary · with Portal Biotechnologies, Kiral Medicines, AIRNA +3 more Talk Thu Oct 1 4:05pm–4:35pm Label-Free Single-Cell Buoyant Mass Profiling Uncovers Hidden T-Cell Heterogeneity and Predicts Immunotherapy Response Innovative Discovery Technologies
Biogen Cambridge, MA
biogen.com Large pharma Biotechnology company with marketed medicines for neurological and neurodegenerative diseases.	Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Talk Thu Oct 1 4:05pm–4:35pm Strategic Engineering of TfR1-Mediated Transcytosis Antibodies Against Challenging Targets
Brigham and Women's Hospital Boston, MA
brighamandwomens.org Academic & healthcare Harvard Medical School teaching hospital in Boston and a founding member of the Mass General Brigham health system.	Panel Thu Oct 1 7:30am–8:15am Drug Discovery for Healthy Aging Plenary · with Wyss Institute, Rising Tide Strategies Emerging drug targets Talk Thu Oct 1 9:05am–9:35am Nanodisc-Based Platform for HLA Antibody Identification Antibodies Against Challenging Targets
Johns Hopkins University Baltimore, MD
	Talk Wed Sep 30 10:05am–10:35am Tailored Signaling Efficacies by Exploiting the Molecular Basis of GPCR Partial Agonism Lead Generation Strategies Talk Wed Sep 30 2:35pm–3:05pm Biofloating: A Cell-based Workflow for the Discovery of Antibodies Targeting Multi-pass Transmembrane Proteins Antibodies Against Challenging Targets
KT Kainova Therapeutics
	Talk Tue Sep 29 8:35am–9:05am Development and Comprehensive Characterization of DT-7012, a Highly Differentiated Anti-CCR8-Depleting Antibody in Immuno-Oncology Antibodies Against Challenging Targets Talk Wed Sep 30 12:20pm–12:50pm MC4R-BAPC: Revisiting an Old Target for Obesity Lead Generation Strategies
National Institutes of Health Bethesda, Maryland
nih.gov Gov/NGO US federal medical research agency; its institutes include NCATS and NIAID.	Talk Wed Sep 30 12:20pm–12:50pm Context-Specific Inhibition of CC Chemokine Receptor 2 Antibodies Against Challenging Targets Talk Wed Sep 30 2:35pm–3:05pm A Platform of Functional Human 3D Neural Cellular Systems for Disease Modeling and Drug Screening Innovative Discovery Technologies
Aureka Biotechnologies
aurekabio.com Biotech AI-driven start-up discovering antibody therapeutics, including GPCR modulators, for cardiometabolic and inflammatory diseases.	Chair Tue Sep 29 1:45pm–1:50pm Chairperson’s Remarks Antibodies Against Challenging Targets Talk Tue Sep 29 2:20pm–2:50pm Engineering Function: AI-Designed Antibodies that Modulate GPCRs Antibodies Against Challenging Targets Panel Wed Sep 30 7:30am–8:15am The Future of Functional Biologics: How AI is Changing Target Discovery, Design, and Therapeutic Modulation Antibodies Against Challenging Targets
Domainex Cambridge, UK	◆Corporate Sponsor
domainex.co.uk CROs & CDMOsCorporate Sponsor UK contract research organisation providing integrated drug discovery: medicinal chemistry, protein science, assays and direct-to-biology screening.	Booth Exhibiting at Booth 503 Tue, Sep 293:50pm–7:00pmWed, Sep 3011:05am–4:50pmThu, Oct 111:05am–2:15pm Talk Tue Sep 29 3:35pm–3:50pm Cutting out the Middleman: Accelerating Drug Discovery with Direct-to-Biology Lead Generation Strategies Talk Wed Sep 30 3:35pm–3:50pm PureDisc: Unlocking Membrane Proteins for Structural Biology and Biophysics Utilizing Native Membrane Polymer Nanodiscs Antibodies Against Challenging Targets
Abalone Bio Emeryville, CA
abalonebio.com Biotech Develops antibodies that activate hard-to-drug targets such as GPCRs, using library-scale functional selection and machine learning.	Talk Wed Sep 30 3:05pm–3:35pm Metabolic Class B GPCR Agonist Antibodies Discovered by Library-Scale Functional Selection Antibodies Against Challenging Targets Chair Thu Oct 1 9:00am–9:05am Chairperson's Remarks Antibodies Against Challenging Targets